Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 05, 2023 Filed Aug 8, 2023 21:31 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionCommon Stock | 51,516 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-016040 · form4.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,310,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: Includes 7,128 shares of restricted stock for which the risk of forfeiture will lapse on August 6, 2024. Read SEC document |
| August 05, 2023 Filed Aug 8, 2023 21:29 UTC |
Hippel JamesCFO
|
Exercise / conversionRestricted Stock Units · Derivative | 12,876 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-016038 · form4.xml · derivative · entry 10 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,876 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F3 · derivative.exercise_date: On 8/5/2023, the Board of Directors certified vesting of 12,876 performance RSUs. F3 · derivative.expiration_date: On 8/5/2023, the Board of Directors certified vesting of 12,876 performance RSUs. Read SEC document |
| August 05, 2023 Filed Aug 8, 2023 21:29 UTC |
Hippel JamesCFO
|
Tax withholdingCommon Stock | 6,335 | $82.17 | $520,546.95 |
DisclosureSEC source: 0001062993-23-016038 · form4.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,561 Read SEC document |
| August 05, 2023 Filed Aug 8, 2023 21:29 UTC |
Hippel JamesCFO
|
Exercise / conversionCommon Stock | 12,876 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-016038 · form4.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,896 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2023 Filed Aug 8, 2023 21:28 UTC |
Kelderman KimPres. Diagnostics & Genom
|
Exercise / conversionRestricted Stock Units · Derivative | 8,060 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-016036 · form4.xml · derivative · entry 10 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,060 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: On 8/5/2023, the Board of Directors certified vesting of 8,060 performance RSUs. F3 · derivative.expiration_date: On 8/5/2023, the Board of Directors certified vesting of 8,060 performance RSUs. Read SEC document |
| August 05, 2023 Filed Aug 8, 2023 21:28 UTC |
Kelderman KimPres. Diagnostics & Genom
|
Tax withholdingCommon Stock | 4,139 | $82.17 | $340,101.63 |
DisclosureSEC source: 0001062993-23-016036 · form4.xml · nonDerivative · entry 2 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,125 Read SEC document |
| August 05, 2023 Filed Aug 8, 2023 21:28 UTC |
Kelderman KimPres. Diagnostics & Genom
|
Exercise / conversionCommon Stock | 8,060 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-016036 · form4.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,264 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2023 Filed Jul 25, 2023 21:27 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
SaleCommon Stock | 80,000 | $88.36 | $7,069,024.00 |
DisclosureSEC source: 0001062993-23-015315 · form4.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,258,766 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.00 to $88.95 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: Includes (i) 11,448 shares of restricted stock for which the risk of forfeiture will lapse on August 5, 2023; and (ii) 14,248 shares of restricted stock for which the risk of forfeiture will lapse as to 7,128 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 22:38 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 616,676 | $0.00 Strike: $26.65 | $0.00 |
DisclosureSEC source: 0001062993-23-014515 · form4.xml · derivative · entry 5 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 616,676 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 22:38 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Tax withholdingCommon Stock | 390,727 | $81.63 | $31,895,045.01 |
DisclosureSEC source: 0001062993-23-014515 · form4.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,338,766 F1 · ownership.direct: Includes (i) 11,448 shares of restricted stock for which the risk of forfeiture will lapse on August 5, 2023; and (ii) 14,248 shares of restricted stock for which the risk of forfeiture will lapse as to 7,128 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 22:38 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionCommon Stock | 616,676 | $26.65 | $16,434,415.40 |
DisclosureSEC source: 0001062993-23-014515 · form4.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,729,493 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: Includes (i) 11,448 shares of restricted stock for which the risk of forfeiture will lapse on August 5, 2023; and (ii) 14,248 shares of restricted stock for which the risk of forfeiture will lapse as to 7,128 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:07 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
SaleCommon Stock | 322 | $83.00 | $26,726.00 |
DisclosureSEC source: 0001062993-23-013263 · form4.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,112,817 F1 · ownership.direct: Includes (i) 11,448 shares of restricted stock for which the risk of forfeiture will lapse on August 5, 2023; and (ii) 14,248 shares of restricted stock for which the risk of forfeiture will lapse as to 7,128 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| April 28, 2023 Filed May 2, 2023 20:49 UTC |
HIGGINS JOHN LDirector
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $21.85 | $0.00 |
DisclosureSEC source: 0001062993-23-009932 · form4.xml · derivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2023-10-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2023 Filed May 2, 2023 20:49 UTC |
HIGGINS JOHN LDirector
|
Tax withholdingCommon Stock | 4,377 | $79.88 | $349,634.76 |
DisclosureSEC source: 0001062993-23-009932 · form4.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,983 Read SEC document |
| April 28, 2023 Filed May 2, 2023 20:49 UTC |
HIGGINS JOHN LDirector
|
Exercise / conversionCommon Stock | 16,000 | $21.85 | $349,600.00 |
DisclosureSEC source: 0001062993-23-009932 · form4.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,360 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2023 Filed Apr 21, 2023 20:02 UTC |
Nusse RoelandDirector
|
GiftCommon Stock | 377 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-009442 · form4.xml · nonDerivative · entry 1 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,811 Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 20:59 UTC |
Bohnen ShaneSVP - General Counsel
|
GrantStock Option (right to buy) · Derivative | 3,928 | $0.00 Strike: $73.76 | $0.00 |
DisclosureSEC source: 0001062993-23-008580 · form4.xml · derivative · entry 2 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,928 Underlying: Common Stock · 3,928 shares Expires 2033-04-03 F3 · derivative.exercise_date: Options to purchase 982 shares vest on each of 4/3/24, 4/3/25, 4/3/26 and 4/3/27. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 20:59 UTC |
Bohnen ShaneSVP - General Counsel
|
GrantRestricted Stock Units · Derivative | 6,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-008580 · form4.xml · derivative · entry 1 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,778 Underlying: Common Stock · 6,778 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: 2,259 shares vest on 4/3/24, 2,260 shares vest on 4/3/25 and 2,259 shares vest on 4/3/26. F2 · derivative.expiration_date: 2,259 shares vest on 4/3/24, 2,260 shares vest on 4/3/25 and 2,259 shares vest on 4/3/26. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 21:37 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 407,364 | $0.00 Strike: $26.65 | $0.00 |
DisclosureSEC source: 0001062993-23-000628 · form4.xml · derivative · entry 5 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 616,676 Underlying: Common Stock · 407,364 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 21:37 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Tax withholdingCommon Stock | 255,837 | $84.39 | $21,590,084.43 |
DisclosureSEC source: 0001062993-23-000628 · form4.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,113,139 Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 21:37 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionCommon Stock | 407,364 | $26.65 | $10,856,250.60 |
DisclosureSEC source: 0001062993-23-000628 · form4.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,368,976 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 11,448 shares of restricted stock for which the risk of forfeiture will lapse on August 5, 2023; and (ii) 14,248 shares of restricted stock for which the risk of forfeiture will lapse as to 7,128 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| December 08, 2022 Filed Dec 9, 2022 21:48 UTC |
Furlow Brenda S.SVP - GENERAL COUNSEL
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 7,450 | $0.00 Strike: $31.26 | $0.00 |
DisclosureSEC source: 0001415889-22-012330 · form4-12092022_091248.xml · derivative · entry 8 Furlow Brenda S. · CIK 0001443851 · SVP - GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,762 Underlying: Common Stock · 7,450 shares Expires 2024-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| December 08, 2022 Filed Dec 9, 2022 21:48 UTC |
Furlow Brenda S.SVP - GENERAL COUNSEL
|
SaleCommon Stock | 7,450 | $82.12 | $611,810.39 |
DisclosureSEC source: 0001415889-22-012330 · form4-12092022_091248.xml · nonDerivative · entry 4 Furlow Brenda S. · CIK 0001443851 · SVP - GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,092 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 82.0000 to 82.4900, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 08, 2022 Filed Dec 9, 2022 21:48 UTC |
Furlow Brenda S.SVP - GENERAL COUNSEL
|
Exercise / conversionCommon Stock | 7,450 | $31.26 | $232,905.63 |
DisclosureSEC source: 0001415889-22-012330 · form4-12092022_091248.xml · nonDerivative · entry 3 Furlow Brenda S. · CIK 0001443851 · SVP - GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 21:48 UTC |
Furlow Brenda S.SVP - GENERAL COUNSEL
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 800 | $0.00 Strike: $31.26 | $0.00 |
DisclosureSEC source: 0001415889-22-012330 · form4-12092022_091248.xml · derivative · entry 7 Furlow Brenda S. · CIK 0001443851 · SVP - GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,212 Underlying: Common Stock · 800 shares Expires 2024-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 21:48 UTC |
Furlow Brenda S.SVP - GENERAL COUNSEL
|
SaleCommon Stock | 800 | $82.01 | $65,605.04 |
DisclosureSEC source: 0001415889-22-012330 · form4-12092022_091248.xml · nonDerivative · entry 2 Furlow Brenda S. · CIK 0001443851 · SVP - GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,092 Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 21:48 UTC |
Furlow Brenda S.SVP - GENERAL COUNSEL
|
Exercise / conversionCommon Stock | 800 | $31.26 | $25,010.00 |
DisclosureSEC source: 0001415889-22-012330 · form4-12092022_091248.xml · nonDerivative · entry 1 Furlow Brenda S. · CIK 0001443851 · SVP - GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,892 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 27, 2022 Filed Oct 31, 2022 21:24 UTC |
HIGGINS JOHN LDirector
|
GrantStock Options (Right to Buy) · Derivative | 865 | $0.00 Strike: $295.77 | $0.00 |
DisclosureSEC source: 0001415889-22-010918 · form4-10312022_021059.xml · derivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 865 Underlying: Common Stock · 865 shares Expires 2032-10-27 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/27/22) or the date of Bio-Techne's 2023 annual meeting of shareholders. Read SEC document |
| October 27, 2022 Filed Oct 31, 2022 21:24 UTC |
HIGGINS JOHN LDirector
|
GrantCommon Stock | 338 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-010918 · form4-10312022_021059.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,840 Read SEC document |
| October 27, 2022 Filed Oct 31, 2022 21:22 UTC |
BAUMGARTNER ROBERT VDirector
|
GrantStock Options (Right to Buy) · Derivative | 865 | $0.00 Strike: $295.77 | $0.00 |
DisclosureSEC source: 0001415889-22-010917 · form4-10312022_021035.xml · derivative · entry 2 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 865 Underlying: Common Stock · 865 shares Expires 2032-10-27 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/27/2022) or the date of Bio-Techne's 2023 annual meeting of shareholders. Read SEC document |
| October 27, 2022 Filed Oct 31, 2022 21:22 UTC |
BAUMGARTNER ROBERT VDirector
|
GrantCommon Stock | 338 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-010917 · form4-10312022_021035.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,444 Read SEC document |
| October 27, 2022 Filed Oct 31, 2022 21:21 UTC |
Vessey RupertDirector
|
GrantStock Options (Right to Buy) · Derivative | 865 | $0.00 Strike: $295.77 | $0.00 |
DisclosureSEC source: 0001415889-22-010916 · form4-10312022_021043.xml · derivative · entry 2 VESSEY RUPERT · CIK 0001677618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 865 Underlying: Common Stock · 865 shares Expires 2032-10-27 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/27/2022) or the date of Bio-Techne's 2023 annual meeting of shareholders. Read SEC document |
| October 27, 2022 Filed Oct 31, 2022 21:21 UTC |
Vessey RupertDirector
|
GrantCommon Stock | 338 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-010916 · form4-10312022_021043.xml · nonDerivative · entry 1 VESSEY RUPERT · CIK 0001677618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,565 Read SEC document |
| October 27, 2022 Filed Oct 31, 2022 21:20 UTC |
Nusse RoelandDirector
|
GrantStock Options (Right to Buy) · Derivative | 865 | $0.00 Strike: $295.77 | $0.00 |
DisclosureSEC source: 0001415889-22-010915 · form4-10312022_021026.xml · derivative · entry 2 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 865 Underlying: Common Stock · 865 shares Expires 2032-10-27 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/27/2022) or the date of Bio-Techne's 2023 annual meeting of shareholders. Read SEC document |
| October 27, 2022 Filed Oct 31, 2022 21:20 UTC |
Nusse RoelandDirector
|
GrantCommon Stock | 338 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-010915 · form4-10312022_021026.xml · nonDerivative · entry 1 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,297 Read SEC document |
| October 27, 2022 Filed Oct 31, 2022 21:19 UTC |
KEEGAN JOSEPH DDirector
|
GrantStock Options (Right to Buy) · Derivative | 865 | $0.00 Strike: $295.77 | $0.00 |
DisclosureSEC source: 0001415889-22-010914 · form4-10312022_021040.xml · derivative · entry 2 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 865 Underlying: Common Stock · 865 shares Expires 2032-10-27 F1 · derivative.exercise_date: This option vests on the earlier of the one year anniversary of the grant date (10/27/2022) or the date of Bio-Techne's 2023 annual meeting of shareholders. Read SEC document |
| October 27, 2022 Filed Oct 31, 2022 21:19 UTC |
KEEGAN JOSEPH DDirector
|
GrantCommon Stock | 338 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-010914 · form4-10312022_021040.xml · nonDerivative · entry 1 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,671 Read SEC document |
| October 27, 2022 Filed Oct 31, 2022 21:18 UTC |
Seth AlpnaDirector
|
GrantStock Options (Right to Buy) · Derivative | 865 | $0.00 Strike: $295.77 | $0.00 |
DisclosureSEC source: 0001415889-22-010912 · form4-10312022_021056.xml · derivative · entry 2 Seth Alpna · CIK 0001721020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 865 Underlying: Common Stock · 865 shares Expires 2032-10-27 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/27/2022) or the date of Bio-Techne's 2023 annual meeting of shareholders. Read SEC document |
| October 27, 2022 Filed Oct 31, 2022 21:18 UTC |
Seth AlpnaDirector
|
GrantCommon Stock | 338 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-010912 · form4-10312022_021056.xml · nonDerivative · entry 1 Seth Alpna · CIK 0001721020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,671 Read SEC document |
| October 27, 2022 Filed Oct 31, 2022 21:19 UTC |
Bushman Julie LDirector
|
GrantStock Options (Right to Buy) · Derivative | 865 | $0.00 Strike: $295.77 | $0.00 |
DisclosureSEC source: 0001415889-22-010913 · form4-10312022_021052.xml · derivative · entry 2 Bushman Julie L · CIK 0001518599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 865 Underlying: Common Stock · 865 shares Expires 2032-10-27 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/27/2022) or the date of Bio-Techne's 2023 annual meeting of shareholders. Read SEC document |
| October 27, 2022 Filed Oct 31, 2022 21:19 UTC |
Bushman Julie LDirector
|
GrantCommon Stock | 338 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-010913 · form4-10312022_021052.xml · nonDerivative · entry 1 Bushman Julie L · CIK 0001518599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,012 Read SEC document |
| October 27, 2022 Filed Oct 31, 2022 21:16 UTC |
STEER RANDOLPH CDirector
|
GrantStock Options (Right to Buy) · Derivative | 865 | $0.00 Strike: $295.77 | $0.00 |
DisclosureSEC source: 0001415889-22-010911 · form4-10312022_021014.xml · derivative · entry 2 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 865 Underlying: Common Stock · 865 shares Expires 2032-10-27 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/27/22) or the date of Bio-Techne's 2023 annual meeting of shareholders. Read SEC document |
| October 27, 2022 Filed Oct 31, 2022 21:16 UTC |
STEER RANDOLPH CDirector
|
GrantCommon Stock | 338 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-010911 · form4-10312022_021014.xml · nonDerivative · entry 1 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,644 Read SEC document |
| August 23, 2022 Filed Aug 25, 2022 21:38 UTC |
Kelderman KimPres. Diagnostics & Genom
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 663 | $0.00 Strike: $150.78 | $0.00 |
DisclosureSEC source: 0001437749-22-021367 · rdgdoc.xml · derivative · entry 2 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,848 Underlying: Common Stock · 663 shares Expires 2025-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 23, 2022 Filed Aug 25, 2022 21:38 UTC |
Kelderman KimPres. Diagnostics & Genom
|
Exercise / conversionCommon Stock | 663 | $150.78 | $99,967.14 |
DisclosureSEC source: 0001437749-22-021367 · rdgdoc.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 22:15 UTC |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
GrantStock Options (Right to Buy) · Derivative | 7,400 | $0.00 Strike: $378.08 | $0.00 |
DisclosureSEC source: 0001415889-22-008799 · form4-08172022_030831.xml · derivative · entry 4 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,400 Underlying: Common Stock · 7,400 shares Expires 2029-08-15 F4 · derivative.exercise_date: Options to purchase 1,850 shares vest on each of 8/15/2023, 8/15/2024, 8/51/2025 and 8/15/2026. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 22:15 UTC |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
GrantStock Options (Right to Buy) · Derivative | 5,550 | $0.00 Strike: $378.08 | $0.00 |
DisclosureSEC source: 0001415889-22-008799 · form4-08172022_030831.xml · derivative · entry 3 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,550 Underlying: Common Stock · 5,550 shares Expires 2029-08-15 F3 · derivative.exercise_date: Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 22:15 UTC |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
GrantRestricted Stock Units · Derivative | 1,785 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-008799 · form4-08172022_030831.xml · derivative · entry 2 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,785 Underlying: Common Stock · 1,785 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F3 · derivative.expiration_date: Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:25 UTC |
Kelderman KimPRES. DIAGNOSTICS & GENOM
|
GrantStock Options (Right to Buy) · Derivative | 7,235 | $0.00 Strike: $378.08 | $0.00 |
DisclosureSEC source: 0001415889-22-008784 · form4-08172022_020800.xml · derivative · entry 4 Kelderman Kim · CIK 0001739054 · PRES. DIAGNOSTICS & GENOM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,235 Underlying: Common Stock · 7,235 shares Expires 2029-08-15 F3 · derivative.exercise_date: Options to purchase 1,809 shares vest on each of 8/15/2023, 8/15/2024 and 8/15/2026 and options to purchase 1,808 shares vest on 8/15/2025. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:25 UTC |
Kelderman KimPRES. DIAGNOSTICS & GENOM
|
GrantStock Options (Right to Buy) · Derivative | 5,426 | $0.00 Strike: $378.08 | $0.00 |
DisclosureSEC source: 0001415889-22-008784 · form4-08172022_020800.xml · derivative · entry 3 Kelderman Kim · CIK 0001739054 · PRES. DIAGNOSTICS & GENOM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,426 Underlying: Common Stock · 5,426 shares Expires 2029-08-15 F2 · derivative.exercise_date: Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.